ARTELO BIOSCIENCES INC C/WTS 25/06/2024(TO PUR COM) ARTLW 深 滬
等待開盤 07-31 09:30:00 美东时间
0.0056
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0056
- 總市值 1.87万
- 52周最高 0.1498
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.005
- 委 比 0.00%
- 總股本 334.74万
- 歷史最高 1.25
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.005
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Artelo Biosciences Announces Publication Of Article 'Evaluating The Pharmacokinetics, Efficacy, And Safety Of Low Dose Cannabidiol' In The British Journal Of Clinical Pharmacology
The peer-reviewed evaluation analyzed the efficacy, pharmacokinetics, and safety data obtained from over 50 studies using low-dose cannabidiol (CBD) commonly found in over-the-counter products — and exposes critical limitations and risks of these non-prescription CBD preparations at the doses admini...
07-22 20:41
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
Artelo Biosciences' ART27.13 shows promise in treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer. Nonclinical studies demonstrate its ability to reduce pain-related behaviors and improve body weight and activity levels. Interim results from the CAReS Phase 2 trial highlight its potential broader utility in cancer supportive care, addressing both anorexia cachexia syndrome and chemotherapy-induc...
07-13 13:02
Artelo Biosciences Announces Two Presentations Supporting Development Of ART26.12, Its Selective Fatty Acid Binding Protein 5 Inhibitor
The presentations include results from the Phase 1 clinical study of ART26.12 as well as new biomarker analyses designed to identify indicators of target engagement and pharmacological activity in healthy volunteers. During the first of two presentations, Professor Saoirse E. O'Sullivan, Vice Presid...
06-29 20:48
Artelo Biosciences Presents Metabolite Identification And Profiling Data From Its FABP Inhibitor Candidate ART26.12; Tracks Three Metabolites From Plasma Of Healthy Volunteers Given Single 900 Mg Oral Dose Of ART26.12
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces that Myles Osborn, Lead Medicina...
06-10 19:40
Artelo Biosciences Launches Flexible At-The-Market Offering
The latest announcement is out from Artelo Biosciences ( ($ARTL) ). On May 26, ...
05-28 05:37
Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares rose 7% in pre-market trading as Q2 guidance exceeded expectations.
05-27 17:10
Artelo Biosciences Files Prospectus To Offer Up To $6.53M In Common Stock Via H.C. Wainwright
-SEC Filing
05-27 04:55
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 635.6% to $2.0...
05-18 20:05
